| 000 -LEADER |
|---|
| fixed length control field |
11720nam a22004933i 4500 |
| 001 - CONTROL NUMBER |
|---|
| control field |
EBC31253065 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
MiAaPQ |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20240703144038.0 |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION |
|---|
| fixed length control field |
cr cnu|||||||| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
240628s2022 xx o ||||0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
9780750331753 |
| Qualifying information |
(electronic bk.) |
|
|---|
| Cancelled/invalid ISBN |
9780750331760 |
| 035 ## - SYSTEM CONTROL NUMBER |
|---|
| System control number |
(MiAaPQ)EBC31253065 |
|
|---|
| System control number |
(Au-PeEL)EBL31253065 |
|
|---|
| System control number |
(OCoLC)1429723103 |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
MiAaPQ |
| Language of cataloging |
eng |
| Description conventions |
rda |
| -- |
pn |
| Transcribing agency |
MiAaPQ |
| Modifying agency |
MiAaPQ |
| 100 1# - MAIN ENTRY--PERSONAL NAME |
|---|
| Personal name |
Niazi, Sarfaraz K. |
| 245 10 - TITLE STATEMENT |
|---|
| Title |
Biopharmaceutical Manufacturing, Volume 1 : |
| Remainder of title |
Regulatory Processes. |
| 250 ## - EDITION STATEMENT |
|---|
| Edition statement |
1st ed. |
| 264 #1 - |
|---|
| -- |
Bristol : |
| -- |
Institute of Physics Publishing, |
| -- |
2022. |
|
|---|
| -- |
�2021. |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
1 online resource (448 pages) |
| 336 ## - |
|---|
| -- |
text |
| -- |
txt |
| -- |
rdacontent |
| 337 ## - |
|---|
| -- |
computer |
| -- |
c |
| -- |
rdamedia |
| 338 ## - |
|---|
| -- |
online resource |
| -- |
cr |
| -- |
rdacarrier |
| 490 1# - SERIES STATEMENT |
|---|
| Series statement |
IOP Ebooks Series |
| 505 0# - FORMATTED CONTENTS NOTE |
|---|
| Formatted contents note |
Intro -- Preface -- Outline placeholder -- Overview -- Definitions -- The impact of biopharmaceuticals -- Biopharmaceutical development -- Global markets -- About this book -- Acknowledgments -- Author biographies -- Sarfaraz K Niazi -- Sunitha Lokesh -- Chapter 1 Introduction to biopharmaceuticals -- 1.1 Overview -- 1.1.1 Biosimilars -- 1.1.2 Intellectual property -- 1.1.3 Regulations -- 1.2 Biopharmaceutical molecules -- 1.2.1 Overview -- 1.2.2 Molecular mechanism -- 1.2.3 Therapeutic classification -- 1.2.4 Hormone peptide drugs -- 1.2.5 Human hematopoietic factor -- 1.2.6 Human cytokines -- 1.2.7 Human plasma protein factor -- 1.2.8 Human bone formation protein -- 1.2.9 Recombinant enzymes -- 1.2.10 Antibodies -- 1.3 Protein structure and properties -- 1.3.1 Primary structure -- 1.3.2 Secondary structure -- 1.3.3 Tertiary structure -- 1.3.4 Quaternary structure -- 1.3.5 Post-translational modification (PTM) -- 1.3.6 Association and aggregation -- 1.4 Pharmacokinetic manipulations -- 1.4.1 Protein modification to increase the duration of action -- 1.5 Immunogenicity -- 1.5.1 The immune system -- 1.5.2 Antibodies -- 1.5.3 Antigens -- 1.5.4 Biopharmaceutical immunogenicity -- 1.5.5 Immunogenicity testing -- 1.6 Recombinant expression -- 1.6.1 Understanding DNA and RNA -- 1.7 Gene and cell therapy -- 1.7.1 Gene editing -- 1.8 Conclusion -- Chapter 2 Antibody biopharmaceuticals -- 2.1 Overview -- 2.1.1 Naming -- 2.1.2 Commercial antibodies -- 2.2 The immune system -- 2.2.1 Innate immune system -- 2.2.2 Adaptive immune system -- 2.3 Monoclonal antibodies -- 2.3.1 Mode of action -- 2.4 Types of antibodies -- 2.4.1 Bispecific (BsAbs) -- 2.4.2 Fab fragments and single-chain antibodies -- 2.4.3 Humanized and chimeric mAbs -- 2.4.4 Affinity maturation -- 2.4.5 Antigenized antibodies -- 2.4.6 IgG1 fusion proteins -- 2.4.7 Drug or toxin conjugation. |
|
|---|
| Formatted contents note |
2.5 Development of antibodies -- 2.5.1 Endogenous method: single B-cell -- 2.5.2 Exogenous methods -- 2.5.3 Mouse hybridoma -- 2.5.4 Transgenic mice -- 2.5.5 Surface display libraries -- 2.5.6 Recombinant expression -- 2.6 Conclusion -- 2.7 Databases relevant to antibodies -- Chapter 3 Gene and cell therapy -- 3.1 Overview -- 3.2 Gene therapy -- 3.2.1 Methodologies -- 3.2.2 Risks of gene therapy -- 3.2.3 Gene-editing technologies -- 3.2.4 Vector manufacturing -- 3.2.5 DNA vaccines -- 3.2.6 mRNA vaccines -- 3.3 Cell therapy -- 3.3.1 Types of cell therapies -- 3.3.2 CAR-T treatment (cellular immunotherapy) -- 3.3.3 Allogenic cell therapy -- 3.4 Regulatory considerations -- 3.4.1 Development and characterization of cell populations for administration -- 3.4.2 Characterization and release testing of cellular gene therapy products -- 3.4.3 Additional possible applications: radioisotopes or toxins added to cell preparations -- 3.4.4 Vector production, characterization, and release testing for gene therapy -- 3.4.5 Construction and characterization of vectors -- 3.4.6 Vector manufacturing system -- 3.4.7 Viral master banks -- 3.4.8 Lot-to-lot distribution vector testing and specifications -- 3.4.9 Issues in gene therapy related to specific vector classes -- 3.5 Conclusion -- Chapter 4 Formulation of biopharmaceuticals -- 4.1 Overview -- 4.2 Structural instability -- 4.2.1 Basis -- 4.2.2 Physical degradation -- 4.2.3 Chemical degradation -- 4.3 Formulation composition -- 4.3.1 Route of administration -- 4.3.2 Excipients and properties -- 4.3.3 Liquid formulations -- 4.3.4 Lyophilized formulations -- 4.4 Delivery routes -- 4.4.1 Intravenous -- 4.4.2 Subcutaneous -- 4.4.3 Oral -- 4.4.4 Nasal/pulmonary -- 4.4.5 Transdermal -- 4.4.6 Ocular -- 4.4.7 Rectal -- 4.5 Formulation technologies -- 4.5.1 Hydrogels and in situ forming gels -- 4.5.2 Nanoparticles. |
|
|---|
| Formatted contents note |
4.5.3 Liposome -- 4.5.4 Higher concentration formulations -- 4.6 Examples of formulation -- 4.7 Conclusion -- Appendix A: Physicochemical properties of proteins and peptides approved by FDA -- Chapter 5 Biopharmaceutical development cycle -- 5.1 Overview -- 5.2 The US drug development process -- 5.2.1 Early drug discovery -- 5.2.2 Pharmacopoeia -- 5.2.3 Preclinical research -- 5.2.4 Investigational new drug application -- 5.2.5 Clinical research -- 5.2.6 Regulatory review, approval, and post-marketing safety surveillance -- 5.3 Drug development in Europe -- 5.3.1 Research initiation -- 5.3.2 Testing new medicines -- 5.3.3 EMA influence in development -- 5.3.4 Scientific advice -- 5.3.5 Scientific advice for studies -- 5.3.6 EMA providing other advice -- 5.3.7 How is scientific advice paid for? -- 5.3.8 What happens during scientific advice? -- 5.3.9 Who's involved in scientific advice? -- 5.3.10 Is there any involvement of patients in scientific advice? -- 5.3.11 Is it true that providing scientific advice has an impact on the EMA's assessment of the medicine? -- 5.3.12 What does the EMA say about the results of scientific advice? -- 5.3.13 What safeguards are in place to protect experts' independence during scientific advice? -- 5.3.14 Details of the procedure based on scientific advice -- 5.3.15 What happens before a medicine evaluation begins? -- 5.3.16 In a marketing authorisation application, what information must be provided? -- 5.3.17 What sources do you have for medical data? -- 5.3.18 What is the fundamental premise that underpins a medicine's evaluation? -- 5.3.19 Who is responsible for evaluating marketing authorisation applications? -- 5.3.20 How does the CHMP work? -- 5.3.21 Is it possible for the CHMP to ask for extra information during the evaluation? -- 5.3.22 What other resources does the CHMP have?. |
|
|---|
| Formatted contents note |
5.3.23 What role do patients and healthcare providers play? -- 5.3.24 What safeguards are in place to protect the independence of experts? -- 5.3.25 How did the CHMP arrive at its final conclusion? -- 5.3.26 What information is made public throughout the examination of new medicines and after a decision is reached? -- 5.3.27 A medicine's evaluation calendar -- 5.3.28 Further assessment -- 5.3.29 Discussion and comment at the end -- 5.3.30 Re-examination -- 5.3.31 Who grants EU-wide marketing authorization? -- 5.3.32 Who makes decisions on patient access to medicines? -- 5.3.33 How is the safety of a medicine ensured once it has been put on the market? -- 5.4 Japanese drug approval process -- 5.4.1 Overview -- 5.4.2 New drug approval (NDA) application -- 5.5 Conclusion -- Chapter 6 Biosimilar biopharmaceuticals -- 6.1 Overview -- 6.2 Biosimilarity -- 6.3 Regulatory guidance -- 6.3.1 Background -- 6.3.2 Latin America -- 6.3.3 Canada -- 6.3.4 The World Health Organization (WHO) -- 6.3.5 India -- 6.3.6 Australia -- 6.3.7 Japan -- 6.3.8 Korea -- 6.3.9 Iran -- 6.3.10 EU -- 6.3.11 United States -- 6.4 Development master plan -- 6.4.1 Choice of product -- 6.4.2 Qualification of product -- 6.4.3 Public domain knowledge -- 6.4.4 Manufacturing plan and facility -- 6.4.5 Analytical testing -- 6.4.6 Nonclinical pharmacology -- 6.4.7 Clinical pharmacology -- 6.4.8 Clinical immunogenicity -- 6.4.9 Residual uncertainty -- 6.4.10 Clinical safety and efficacy -- 6.4.11 Post-market surveillance -- 6.5 Interchangeability and substitution -- 6.6 Analytical assessment -- 6.6.1 Introduction -- 6.6.2 Sources of variation -- 6.6.3 Product- or process-related substances -- 6.6.4 Method sensitivity -- 6.6.5 Comparative testing -- 6.6.6 Side-by-side testing -- 6.6.7 Heterogeneity -- 6.6.8 Structure confirmation -- 6.6.9 Acceptance criteria -- 6.6.10 Orthogonal testing. |
|
|---|
| Formatted contents note |
6.6.11 Accountability of lots -- 6.6.12 Critical quality attributes -- 6.6.13 Reference standard -- 6.6.14 The finished drug product -- 6.6.15 Excipients -- 6.6.16 Stability -- 6.6.17 ICH -- 6.6.18 Examples of test methods -- 6.6.19 Risk assessment -- 6.6.20 Statistical considerations -- 6.7 Functional assessment -- 6.7.1 Orthogonal studies -- 6.7.2 Lots tested -- 6.8 In vivo assessment -- 6.8.1 Determination of the needs for in vivo studies -- 6.8.2 In vivo animal studies -- 6.9 Clinical pharmacology assessment -- 6.9.1 Introduction -- 6.9.2 Scope of studies -- 6.9.3 Study plan -- 6.9.4 Dose selection -- 6.9.5 Route of administration -- 6.9.6 Pharmacokinetic parameters -- 6.9.7 New approach to PK analysis -- 6.9.8 PK/PD waivers -- 6.9.9 Pharmacodynamic parameters -- 6.9.10 Statistical treatment of PK and PD results -- 6.9.11 Assay considerations -- 6.9.12 Reserve samples -- 6.9.13 Examples of pharmacokinetic studies -- 6.10 Clinical immunogenicity assessment -- 6.10.1 Introduction -- 6.10.2 Immunogenicity investigation -- 6.10.3 Safety and efficacy correlation -- 6.10.4 Management of immunogenicity testing -- 6.10.5 Examples of studies -- 6.11 Clinical efficacy assessment -- 6.11.1 Introduction -- 6.11.2 Residual uncertainty -- 6.11.3 Waivers -- 6.11.4 Study types -- 6.11.5 Selection of study protocols -- 6.12 Extrapolation of clinical data across indications -- 6.12.1 Extrapolation across indications -- 6.12.2 Additional conditions of use -- 6.13 Conclusion -- Chapter 7 Intellectual property issues for scientists -- 7.1 Overview -- 7.1.1 Patent landscape -- 7.2 Patent law basics -- 7.2.1 Pharmaceutical patenting practices -- 7.3 US patent elements -- 7.3.1 Title of invention -- 7.3.2 Cross-reference to related applications -- 7.3.3 Statement regarding federally sponsored research or development -- 7.3.4 Background of the invention. |
|
|---|
| Formatted contents note |
7.3.5 Brief summary of the invention. |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc |
This volume covers the regulatory processes involved in producing a GMP (Good Manufacturing Practice) biopharmaceutical product for commercial distribution, including areas of current GMP, registration, and legal and ethical considerations. Emerging trends in the technology and regulatory compliance are also discussed, with advice on establishing efficient manufacturing facilities. Intended for practitioners in the commercial biopharmaceutical manufacturing industry, the text is an ideal resource for practitioners looking to develop their ability to manufacture biopharmaceutical products at a large scale. |
| 588 ## - |
|---|
| -- |
Description based on publisher supplied metadata and other sources. |
| 590 ## - LOCAL NOTE (RLIN) |
|---|
| Local note |
Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries. |
| 655 #4 - INDEX TERM--GENRE/FORM |
|---|
| Genre/form data or focus term |
Electronic books. |
| 700 1# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Lokesh, Sunitha. |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY |
|---|
| Display text |
Print version: |
| Main entry heading |
Niazi, Sarfaraz K. |
| Title |
Biopharmaceutical Manufacturing, Volume 1 |
| Place, publisher, and date of publication |
Bristol : Institute of Physics Publishing,c2022 |
| International Standard Book Number |
9780750331760 |
| 797 2# - LOCAL ADDED ENTRY--CORPORATE NAME (RLIN) |
|---|
| Corporate name or jurisdiction name as entry element |
ProQuest (Firm) |
| 830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE |
|---|
| Uniform title |
IOP Ebooks Series |
| 856 40 - ELECTRONIC LOCATION AND ACCESS |
|---|
| Uniform Resource Identifier |
https://ebookcentral.proquest.com/lib/kliuc-ebooks/detail.action?docID=31253065 |
| Public note |
Click to View |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
|
| Koha item type |
E-book |
